Michelson Diagnostics is a technology company.
Michelson Diagnostics has raised $7.0M across 3 funding rounds.
Michelson Diagnostics has raised $7.0M in total across 3 funding rounds.
Michelson Diagnostics has raised $7.0M in total across 3 funding rounds.
Michelson Diagnostics's investors include Edge VC.
Michelson Diagnostics is a UK-based medical device company specializing in multi-beam Optical Coherence Tomography (OCT) technology for dermatology.[1][2][3] Its flagship product, the VivoSight OCT scanner (including models like VivoSight Dx and Dx Pro), is a point-of-care device that provides high-resolution, real-time cross-sectional images of skin tissue up to 1-1.5 mm deep, enabling clinicians to diagnose and monitor conditions like non-melanoma skin cancer (NMSC) without biopsies.[1][2][4][6] It serves dermatologists, researchers, and clinicians by solving the problem of inaccurate surface-based assessments, allowing earlier, more precise treatment decisions and reducing invasive procedures.[1][6]
The company generates revenue from VivoSight's commercial application in NMSC diagnosis, with ongoing advancements like upgraded software for lesion analysis and angiographic imaging to visualize morphologic changes.[1][6] Growth includes product launches (e.g., VivoSight Dx in 2015) and design enhancements for better user experience, positioning it as a leader in non-invasive skin imaging.[2]
Michelson Diagnostics was founded in March 2006 in Orpington, UK, by five physicists and engineers expert in laser scanning, initially to develop a hand-held cancer scanner using OCT technology.[3][5][6] In just four years, the team built, tested, and secured regulatory clearance for their system, demonstrating rapid progress from concept to market.[3] Early focus was on multi-beam OCT for dermatology, leading to the launch of the VivoSight scanner, with pivotal upgrades like new software in 2014 for skin lesion investigation and the VivoSight Dx at a 2015 dermatology congress.[1][2]
CEO Jon Holmes has emphasized providing cutting-edge tools for accurate skin condition diagnosis, building on collaborations with dermatologists to refine usability and patient experience.[1][2]
Michelson Diagnostics rides the trend toward non-invasive, real-time diagnostics in dermatology, fueled by rising NMSC incidence and demand for precision medicine.[1][4] OCT's timing aligns with advances in laser optics and AI-enhanced imaging, outpacing traditional biopsy methods amid growing tele-dermatology and point-of-care needs.[2][6] Market forces like aging populations and skin cancer prevalence favor its expansion, influencing the ecosystem by setting OCT as a dermatology standard and enabling research into epithelial diseases.[1][6]
Michelson Diagnostics is poised to expand VivoSight's adoption with Dx Pro's angiographic capabilities, targeting broader clinical trials, academic research, and global dermatology markets.[6] Trends like integrated AI for automated analysis and portable OCT will shape its path, potentially evolving into multi-application platforms for other epithelial cancers. Its influence may grow by partnering with medtech firms, solidifying non-invasive imaging as dermatology's core tool and enhancing early detection outcomes.[1][6]
Michelson Diagnostics has raised $7.0M across 3 funding rounds. Most recently, it raised $3.0M Series B in February 2015.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2015 | $3.0M Series B | Edge VC | |
| Mar 1, 2012 | $950K Venture Round | Edge VC | |
| Oct 1, 2010 | $3.0M Series A | Edge VC |